December 7, 2024
Avant Technologies and Ainnova Advancing Proprietary Retinal Camera to Market With Vision AI Software
Avant Technologies Inc.
Avant Technologies Inc.

LAS VEGAS, Nov. 20, 2024 (GLOBE NEWSWIRE) — Avant Technologies Inc. (OTCQB: AVAI) (“Avant” or the “Company”), and its partner Ainnova Tech, Inc. (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the companies will advance Ainnova’s proprietary low-cost retinal camera, which will be used for fundus photography, and seamlessly packaged together with Ainnova’s Vision AI software platform for commercialization. By combining the two technologies, Ainnova’s versatile camera will provide precise retinal scans to its AI software leading to even more accurate data.

Vision AI is a powerful cutting-edge, AI-driven platform that can quickly and accurately detect the early markers of a host of diseases by applying AI models to examine imaging data from the eye to expedite earlier detection and allow patients to better manage their disease. The diseases that Vision AI can detect include diabetic retinopathy, other retinopathies, such as glaucoma, macular edema, age-related macular degeneration and other anomalies, as well as other diseases that do not require retinal images, and instead, use other datapoints that Ainnova will integrate into the software like the detection of kidney disease, liver fat, cardiovascular risk, and pre-diabetes.

Currently, Ainnova’s Vision AI software works well with any fundus camera on the market; however, Ainnova and Avant are aiming for exclusivity by developing a lower-cost, easier to use camera that captures retinal images automatically and then uploads those images to the Vision AI software platform, which then produces a “risk report” in mere seconds. Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova, will develop the retinal cameras as part of the joint venture and licensing deal to facilitate the development of Ainnova’s technology portfolio. AAC owns the licensing rights to develop, maintain, and market Ainnova’s technology portfolio in both North America (United States and Canada) and throughout Europe.

Vinicio Vargas, Chief Executive Officer of Ainnova and member of AAC’s Board of Directors, said, “The cost of a fundus camera has always been a barrier to entry into in this market, so our low-cost camera should allow us to not only enter the market, but to capture a large share of the market. To that end, I will be meeting with a leading U.S. provider of digital healthcare solutions to discuss a potential distribution agreement, investment, and regulatory support.”


link

Leave a Reply

Your email address will not be published. Required fields are marked *